Hendrix J D, Parlette H L
Department of Dermatology, University of Virginia School of Medicine, Charlottesville.
Arch Dermatol. 1996 Mar;132(3):295-8. doi: 10.1001/archderm.132.3.295.
Micronodular basal cell carcinoma (BCC) is thought to have a greater potential for clinically surreptitious tumor spread compared with the majority of BCCs that are nodular. However, most supporting data are anecdotal. This study gives objective evidence that micronodular BCCs have wider and deeper tumor extensions than nodular BCCs of similar clinical size. In this retrospective study, 69 cases of micronodular BCC excised by Mohs' micrographic surgery (MMS) were matched to a control group of 69 cases of nodular BCC that were similarly excised. They were paired by site, size, number of recurrences, age, gender, and previous treatment type. The cases were selected and paired by computer from 1070 consecutive BCCs (primary and recurrent) referred for MMS over a 4-year period. The MMS technique allowed us to quantitate and compare the extent of tumor spread using three measurements: the number of surgical stages required for complete removal of the tumor, the width of tissue required to remove subclinical extension of tumor, and the depth of defect at completion of MMS.
Analysis showed the micronodular BCC to have significantly more covert tumor extension, making it more difficult to detect and to eradicate than the nodular BCC. The number of surgical stages required for complete removal of tumor, the width of tissue required to remove subclinical extension of tumor, and the depth of defect at completion of MMS were all greater with micronodular BCCs when compared with nodular BCCs regardless of whether cases were primary or recurrent. These differences were all statistically significant.
Micronodular BCCs can be significantly more destructive than nodular BCCs because tumor extension is difficult to detect clinically. When treating micronodular BCC, clinicians should keep in mind its potential for clandestine invasion.
与大多数结节状基底细胞癌(BCC)相比,微结节状基底细胞癌被认为在临床上具有更大的隐匿性肿瘤扩散潜力。然而,大多数支持数据都是轶事性的。本研究提供了客观证据,表明微结节状BCC比临床大小相似的结节状BCC具有更广泛和更深的肿瘤浸润。在这项回顾性研究中,将69例通过莫氏显微外科手术(MMS)切除的微结节状BCC与69例同样通过该手术切除的结节状BCC对照组进行匹配。它们根据部位、大小、复发次数、年龄、性别和既往治疗类型进行配对。这些病例是从4年期间转诊接受MMS的1070例连续BCC(原发性和复发性)中通过计算机选择并配对的。MMS技术使我们能够使用三种测量方法来量化和比较肿瘤扩散的程度:完全切除肿瘤所需的手术阶段数、切除肿瘤亚临床浸润所需的组织宽度以及MMS完成时缺损的深度。
分析表明,微结节状BCC具有明显更多的隐匿性肿瘤浸润,使其比结节状BCC更难检测和根除。与结节状BCC相比,无论病例是原发性还是复发性,微结节状BCC完全切除肿瘤所需的手术阶段数、切除肿瘤亚临床浸润所需的组织宽度以及MMS完成时缺损的深度都更大。这些差异均具有统计学意义。
微结节状BCC可能比结节状BCC具有更大的破坏性,因为肿瘤浸润在临床上难以检测。在治疗微结节状BCC时,临床医生应牢记其潜在的隐匿性侵袭。